|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Thyroid transcription factor 1 : a marker for lung adenocarcinoma in body cavity fluids显示文摘 | Gomez-Fernandez C Jorda M Delgado PI | 2002 | Cancer2002，96，5： | 1 |
| 2 | Thyroid transcription factor 1 显示文摘 | Gomez-Femandez C Jorda M Delgado PI | 2002 | Cancer2002，96，5： | 1 |
| 3 | Thyroid transcription factor 1 :a marker for lung adenocarcinoma in body cavity fluids显示文摘 | Gomez FC Jorda M Delgado PI | 2002 | Cancer2002，96，5： | 1 |
| 4 | Thyroid transcription factor 1:A marker for lung adenocarcinoma in body cavity fluids显示文摘 | Gomez-Femandez C Jorda M Delgado PI | | 0，，05： | 1 |
| 5 | Laparoscopic-assisted vs. open colectomy for colorectal cancer: Influence on neoplastic cell mobilization显示文摘 | Xavier Bessa M.D. Dr. Antoni Castells M.D. Antonio M. Lacy M.D. J. Ignasi Elizalde M.D. Salvadora Delgado M.D. Loreto Boix Ph.D. Virginia Pi?ol M.D. Maria Pellisé M.D. Juan C. García-Valdecasas M.D. Josep M. Piqué M.D | 2001 | Journal of Gastrointestinal Surgery2001，，1： | 1 |
| 6 | Thyroid transcription factor Ⅰ:a marker for lung adenocarcinoma in body cavity fluids显示文摘 | Gomez FC Jorda M Delgado PI | 2002 | Cancer2002，96，5： | 1 |
| 7 | Thyroid transcription factor l显示文摘 | Gomez-Fernandez C Jorda M Delgado PI | 2002 | Cancer2002，96，5： | 1 |
| 8 | Thyroid transcription factor 1,a marker for lung adenocarcinoma in body cavity fluids显示文摘 | Fernandez CG Jorda M Delgado PI | 2002 | Cancer Cytopathol2002，96，5： | 1 |
| 9 | Epsteim-Barr Virus Associated Primary Central Nervous System Lymphoma in a Child with the Acquired Immunodeficiency Syndrome: a Case Report and Review of the Liferature显示文摘 | Rodriguez MM Delgado PI Petito CK | 1997 | Arch Pathol Lab Med1997，121，12： | 1 |
| 10 | Topical Calendula officinalis L.inhibits inflammatory pain through antioxidant,anti-inflammatory and peripheral opioid mechanisms显示文摘Objective The present study evaluated the antinociceptive activity of Calendula officinalis L.(Ca)cream on inflammatory hypernociception.Methods Creams with different Ca concentrations were tested for their ability to ameliorate pain-related behavior and edema in rats using formalin test,carrageenan(Cg)-induced acute inflammation model,bradykinin(BK)-induced acute inflammation model,and complete Freund’s adjuvant(CFA)-induced chronic inflammation model.Using the formalin test,we also examined the implication of peripheral opioid receptors in the antinociceptive mechanisms of Ca cream,by means of Q-naloxone,a peripherally acting nonselective opioid antagonist.Furthermore,the effects of Ca cream compared with diclofenac on BK-induced edema were examined when the kininase II in tissue was preserved or inhibited by captopril.The local production of redox biomarkers in formalin model,tumor necrosis factor-α(TNF-α)in Cg model and histopathological changes in CFA model were also evaluated.Results A single application of Ca cream at a dose of 10%or 30%(w/w)decreased the formalin-induced licking/biting behavior during both phases of this test in a Q-naloxone-sensitive manner.This effect was associated with the reduction of oxidative stress in the injured paw and the edema associated with the later phase of formalin-induced pain.A single application of Ca cream(10%or 30%)reduced paw edema and thermal hypernociception in Cg-induced acute inflammation,corresponding with a local decrease in TNF-α.Ca cream also inhibited BK-induced spontaneous nociceptive behavior and paw inflammation in both paradigms studied.Repeated applications of Ca cream also decreased CFA-induced chronic inflammation,mechanical hypernociception and histopathological changes in the paw.Conclusion These results reveal the topical antinociceptive and antiedematogenic effects of Ca cream.A modulatory action on peripheral opioid receptors associated with its antioxidant mechanism may be involved,at least in part,in its analgesic effects.These findings may have an impact on the clinical management of painful inflammatory diseases. | Bárbara B.Garrido-Suárez Gabino Garrido Addis Bellma Menéndez Nelson Merino Odalys Valdés Nilia de la Paz Aylema Romero Livan Delgado Miguel D.Fernández Octavio Piñeros RenéDelgado-Hernández | 2023 | Journal of Integrative Medicine2023，21，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员